Banta

BAnta Pharmaceuticals is a biotechnology company focused on developing a new class of therapeutics called biased antagonists for G protein-coupled receptors (GPCRs). Spun out of the University of Illinois Chicago (UIC), the company leverages its proprietary platform to design small molecules that selectively block specific signaling pathways of chemokine receptors while leaving others unaffected. Its lead programs target the CCR3 receptor for the treatment of eosinophilic inflammatory diseases, such as asthma and allergic inflammation. By utilizing biased antagonism, BAnta aims to achieve superior efficacy and reduced side effects compared to traditional balanced antagonists. The company has received support from the National Science Foundation and regional innovation grants to advance its pre-clinical drug discovery efforts.